SeQuant acquistion expands Merck KGaA's chromatography portfolio

May 10, 2008

Merck KGaA (Darmstadt, Germany), a privately-held pharmaceutical and specialist chemicals company, has acquired the assets of chromatographic column developer SeQuant AB (Umea, Sweden). "[The aquisition] offers Merck superb opportunities for the future expansion of the chromatography business," said Klaus Bischoff, head of the Performance and Life Science Chemicals division at Merck.

Merck KGaA (Darmstadt, Germany), a privately-held pharmaceutical and specialist chemicals company, has acquired the assets of chromatographic column developer SeQuant AB (Umea, Sweden). "[The aquisition] offers Merck superb opportunities for the future expansion of the chromatography business," said Klaus Bischoff, head of the Performance and Life Science Chemicals division at Merck. SeQuant is particulary known for its particle technology development for zwitterionic hydrophilic interaction chromatography, or ZIC(R)-HILIC, a proprietary concept that "markedly improves the separation of... chemical compounds," such as inorganic ions and polar organic ions, including peptides, according to the company.